Shares of Health Care sector company Grifols moved -2.4% today, and are now trading at a price of $9.24. The Mid-Cap stock's daily volume was 630,181 compared to its average volume of 1,156,731. The S&P 500 index returned a 0.0% performance.
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company is based in Barcelona and has 23,000 full time employees. Its market capitalization is $7,253,173,760.
4 analysts are following Grifols and have set target prices ranging from $8.93 to $11.8 per share. On average, they have given the company a rating of buy. At today's prices, GRFS is trading -14.06% away from its average analyst target price of $10.76 per share.
Over the last year, GRFS shares have gone down by -1.0%, which represents a difference of -30.1% when compared to the S&P 500. The stock's 52 week high is $12.15 per share and its 52 week low is $5.3. Grifols has averaged free cash flows of $-49055500.0 over the last 5 years, with a mean growth rate of -20.9%. It is likely that the stock will keep following its current negative performance trend while the underlying business is experiencing such poor cash flows.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 208,283 | 548,891 | -340,608 | 38.47 |
| 2022 | -10,867 | 542,718 | -553,585 | -528.2 |
| 2021 | 596,975 | 467,694 | 129,281 | -80.29 |
| 2020 | 1,110,336 | 454,369 | 655,967 | 208.22 |
| 2019 | 568,933 | 1,175,072 | -606,139 | -244.06 |
| 2018 | 737,428 | 316,677 | 420,751 |
